Palobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, Spain · The new facilities, of 200 square meters, consist of an office area next to a fully equipped medicinal...
Navarra – February 2025 – Medibiofarma S.L., a clinical-stage biotechnology company developinga portfolio of new small molecule therapies announced the award of the European CommissionSeal of Excellence...
Navarra – February 2024 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of neurodegenerative diseases and other pathologies announced...
Navarra – May 10, 2023 – Medibiofarma S.L., a clinical-stage biotechnology company developing aportfolio of new therapies for the treatment of gastrointestinal (GI) diseases as well as othercancer and...
Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Support Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment...
Navarra – December 2022 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of cancer and non-cancer diseases announced the first subject...
Medibiofarma has just closed a financing round of 1.2 million euros, supported by the founder’s and other VC partners with proven experience in the field of health and technology, such as Sodena (Public...
Navarra – July 15, 2020 – Medibiofarma S.L., a clinical-stage oncology company developing new immuno-activating therapies for the treatment of cancer today announced the first subject dosed in the Phase 1...
Medibiofarma participated in the “Startup Spotlight” event sponsored by Eli Lilly in the 13th edition of the annual BIO-Europe Spring conference 2019 held in Vienna. Julio Castro, CSO of Medibiofarma, made...